HIGHLIGHTS
- who: Report and collaborators from the Hospital, Port Jefferson, USA have published the research work: Review began 01/24/2023 Review ended 02/05/2023 Published 02/06/2023 u00a9 Copyright, in the Journal: (JOURNAL) of February/06,/2023
- what: 2023 Alqaisi et_al Cureus 15(2): e34696.
- how: Based on these results the authors concluded that an antibody-independent mechanism is likely responsible for thyroid dysfunction secondary to pembrolizumab therapy and may involve T-cell natural killer (NK) cell and/or monocyte-mediated pathways .
- future: Research is needed to understand the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.